Bicycle Therapeutics Ltd (BCYC) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $5.64
• Market Cap: $397.48M
• EPS: $-3.62
• 52-Week High: $11.16
• 52-Week Low: $5.03

Market Sentiment

Bicycle Therapeutics Ltd currently has a Bullish sentiment score of 0.34.

About Bicycle Therapeutics Ltd

Bicycle Therapeutics Ltd (BCYC) is an innovative clinical-stage biopharmaceutical company headquartered in Cambridge, UK, specializing in the development of novel therapeutics utilizing its proprietary bicyclic peptide platform. Targeting significant unmet medical needs across various disease areas, particularly in oncology, Bicycle aims to revolutionize treatment modalities with its distinct approach to drug design. The company boasts a robust pipeline of candidates, underscoring its commitm...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Bicycle Therapeutics Ltd and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does BCYC pay dividends?

Bicycle Therapeutics Ltd (BCYC) does not currently pay a regular dividend.

What is BCYC's market cap?

Bicycle Therapeutics Ltd (BCYC) has a market capitalization of $397.48M with a current stock price of $5.64.